Prof. Patricia A. Kruk

University of South Florida, USA

Email: pkruk@health.usf.edu

Qualifications

1992 Ph.D., University of British Columbia, Medical Sciences

1983 M.Sc., University of Alberta, Zoology

1980 B.Sc., Concordia University, Biological Sciences

Publications (selected)

1. Onursal O, Sisman A, Gilbert N, Kruk P, Guldiken R. Urinary Bcl-2 surface acoustic wave biosensor for early ovarian cancer detection. Sensors, 12: 2012. Doi: 10.3390/s120x0000x.
2. Xu C-X, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ. Mir-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. 2012. JBC, 287: 34970-8, 2012. Doi: 10.1074/jbc.M112.374611. Epub 2012 Aug 27.
3. Shen Z, Ravi K, Jinwal U, Nicosia SV, Kruk P, Xiaohang Z, Bai W. 1,25-dihydroxyvitamin D3 suppresses telomerase expression and human cancer cell survival through miR-498. 2012. JBC, 287: 41297-309, 2012. Doi: 10.1074/jbc.M112.407189. Epub 2012 Oct 10.
4. Woolery KT, Kruk PA. Ovarian Epithelial-Stromal Interactions: Role of Interleukins 1 and 6. Obstet. Gynecol. Intl., in press, 2011.
5. Linger RJ, Kruk PA. BRCA1 16 years later: Risk-associated BRCA1 mutations and their functional implications. FEBS J., 227: 3086-3096, 2010.
6. Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk PA, Nicosia SV. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol., 117: 117-24, 2010.
7. O’Donnell JD, Linger RJ, Kruk PA. BRCA1 del185AG mutant protein, BRAt, up-regulates maspin expression in ovarian epithelial cells. Gynecol. Oncol., 116: 262-268, 2010.
8. Anderson NS, Turner L, Livingston S, Chen R, Nicosia SV, Kruk PA. Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation. J. Ovarian Research, 2: 16 (1-11), 2009.
9. Drenberg C, Livingston S, Chen R, Kruk PA, Nicosia SV. Expression of Semaphorin 3F and its receptors in epithelial ovarian cancer, fallopian tubes, and secondary Mullerian tissues. Obstet. Gynecol. Intl., 2009. Doi: 10.1155/2009/730739.
10. Guo J, Shu S-K, He L, Lee Y-C, Kruk PA, Grenman S, Nicosia SV, Coppola D, Cheng JQ. Deregulation of the IKBK oncogene is associated with tumor progression, poor prognosis and cisplatin resistance in ovarian cancer. Amer. J. Pathol, 175: 324-33, 2009.
11. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, Nicosia SV, Zhang X. Deacetylation of cortactin by Sirt1 promotes cell migration. Oncogene, 28: 445-69, 2009.
12. Anderson NC, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol, 11: 60-7, 2009.
13. O’Donnell JD, Johnson NC, Turbeville TD, Alfonso MY, Kruk PA. BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cancer cells. In Vitro Cell Dev. Biol., 44: 357-67, 2008.
14. Bermudez Y, Yang H, Cheng JQ, Kruk PA. Pyk2/ERK1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor. Growth Factors, 26: 1-11, 2008.
15. Yang H, Kong W, He L, Zhao J-J, O’Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miRNA-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 68: 424-433, 2008.
16. Bermudez Y, Yang H, Saunders BO, Cheng JQ, Nicosia SV, Kruk PA. VEGF- and LPA-induced telomerase activity in human ovarian cancer cells is Sp1-dependent. Gynecol. Oncol., 106: 526-537, 2007.
17. Bermudez Y, Ahmadi S, Lowell NE, Kruk PA. Vitamin E suppresses telomerase activity in ovarian cancer cells. Cancer Detect. Prevent, 31: 119-128, 2007.
18. Bermudez Y, Erasso D, Johnson NC, Alfonso MY, Lowell NE, Kruk PA. Telomerase Confers Resistance to Caspase-Mediated Apoptosis. Clin. Intervent. Aging, 1: 155-167, 2006.